DermaSarra External Analgesic Recalled Nationwide for Bacterial Contamination
DermaSarra external analgesic is recalled nationwide because bottles were contaminated with Burkholderia cepacia bacteria. Consumers should stop using the product immediately.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I recall for microbial contamination, which per the rubric carries a minimum score of 4. The product contains confirmed bacterial contamination with Burkholderia cepacia, but no illnesses or injuries have been reported.
Plain-English summary
DermaSarra, an external analgesic containing 0.5% camphor, is being recalled by the FDA. The product was found to be contaminated with Burkholderia cepacia bacteria.
The recall affects 249 bottles distributed nationwide under lot number 40187.2 with an expiration date of February 2026. The affected product is 222 mL (7.5 fl. oz.) bottles manufactured by DermaRite Industries, LLC, based in North Bergen, New Jersey.
Consumers should stop using this product immediately. If you have used this product and have health concerns, contact a healthcare provider for advice. The product should be discarded or returned to the point of purchase.
The recalled product
- Product
- DermaSarra, External Analgesic, (Camphor 0.5%) 222 mL (7.5 fl. oz.) per bottle, DermaRite Industries LLC, 7777 West Side Avenue, North Bergen, NJ 07047. NDC 61924-189-08
- Manufacturer
- DermaRite Industries, LLC
- Category
- Drug — Topical Analgesic
- Hazard
- burkholderia-cepacia
- microbial-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 40187.2
- Exp. Date 2/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27